Vktx stock forecast 2025

Viking has advanced the subcutaneous formulation of VK2735 into phase 3 trials for obesity, but it's also developing an oral tablet formulation. The company is planning to announce 13-week results from the phase 2 Venture study of the pill version in the second half of 2025. Here’s a breakdown of recent trading of $VKTX stock by insiders over the last 6 months: Compared to small-cap biotech peers, vktx stock forecast 2025 benefits from a lower debt-to-equity ratio, enhancing its financial stability profile.